Bausch Health's RED-C Trials Fail Primary Endpoint, Despite Safety
Event summary
- Bausch Health's Phase 3 RED-C trials for rifaximin SSD in liver cirrhosis patients failed to meet primary endpoints despite being safe and well-tolerated.
- The trials involved over 1,000 patients across 398 sites in 17 countries.
- Bausch Health is reviewing the full dataset to explore potential new development opportunities.
- Cirrhosis ranks as the ninth leading cause of death in the US, per CDC data from October 2024.
The big picture
Bausch Health's failure in the RED-C trials highlights the persistent challenges in developing preventive treatments for hepatic encephalopathy in cirrhosis patients. The setback comes amid a competitive landscape where few approved therapies exist for this indication. The company's ability to extract value from the trial data will be critical in maintaining investor confidence in its R&D capabilities.
What we're watching
- Pipeline Reassessment
- How Bausch Health will pivot its hepatology pipeline following this setback.
- Competitive Dynamics
- Whether rivals will capitalize on the trial failure to gain market share in liver disease treatments.
- Data Utilization
- The pace at which Bausch Health can repurpose the RED-C dataset for future indications or trials.
Our editorial coverage:
Related topics